IMI2-2015-05-01
IMI2-2015-05-01
1 project · €6,000,000 total EU contribution (project-level) · 36 participating organizations · 9 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€6,000,000
Countries active
Participant organizations by country (headquarters in CORDIS).
- UK (9)
- BE (7)
- Germany (6)
- CH (4)
- Netherlands (4)
- Italy (2)
- SE (2)
- France (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- AbbVie1 projects · UK
- ACTELION PHARMACEUTICALS LTD1 projects · CH
- AMGEN LIMITED1 projects · UK
- YAMANOUCHI EUROPE BROCADES PHARMA1 projects · NL
- ASTRAZENECA AB1 projects · SE
- BAYER AKTIENGESELLSCHAFT1 projects · DE
- Bayer Pharma AG1 projects · DE
- FEDERAAL KENNISCENTRUM VOOR DE GEZONDHEIDSZORG FODERALES EXPERTISEZENTRUM DES GESUNDHEIT1 projects · BE
- COLLABORATE PROJECT MANAGEMENT GMBH1 projects · DE
- CSL BEHRING GMBH1 projects · DE
- ELI LILLY AND COMPANY LTD1 projects · UK
- ERASMUS MC1 projects · NL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFER · 115966 | H2020 | €6,000,000 | €358,198 | Details |